IntroductionAnti-staphylococcal penicillins are generally accepted as first-line therapy for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, but their use may be limited by interstitial nephritis and acute kidney injury. Alternatives include first-generation cephalosporins including cefazolin.MethodsWe conducted a retrospective cohort study to compare adverse effects and clinical outcomes among patients with MSSA bacteremia treated with cefazolin or nafcillin. The primary endpoint was acute kidney injury (AKI), defined as a 0.3 mg/dL or 50% increase from baseline.ResultsIncidence of AKI was 27/82 (33%) versus 9/68 (13%) (p = 0.007) in the nafcillin and cefazolin arms, respectively. After adjusting for endocarditis and intensive care unit admission in multivariate logistic regression, nafcillin was an independent predictor of AKI [adj odds ratio (OR) = 2.74; 95% (CI) 1.1–6.6]. Patients who experienced AKI were more likely to have a prolonged intensive care unit stay.ConclusionRisk of nephrotoxicity is increased with nafcillin compared with cefazolin. Cefazolin should considered as a safer alternative to nafcillin for select patients with MSSA bacteremia.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-017-0148-z) contains supplementary material, which is available to authorized users.
We hereby retract this article. In our paper we described discrepant results between ceftolozane-tazobactam Etests and broth microdilution. However, when repeat testing on the same isolates was done for a second, larger study recently published by R. M.
Background Infections due to carbapenem non-susceptible organisms are associated with significant mortality. The objective of this study was to identify modifiable predictors for survival in patients with these infections with a focus on antimicrobial therapies.Methods This was a case–control study at a four-hospital health-system. Patients were evaluated for inclusion if they were ≥18 years with an infection due to a carbapenem non-susceptible organism from November 2013 to October 2016. Exclusion criteria were infections localized to the urinary tract or hospice designation. The primary objective was to identify independent predictors of all cause 30-day mortality. Pharmacodynamic (PD) optimized BL therapy was the exposure of interest, defined as doses administered to patients expected to obtain an estimated target attainment of ≥ ~90% of fT > MIC targets associated with a 1 log kill for the isolated pathogens MIC, based on published PK/PD literature and the renal function of the patient.ResultsA total of 203 patients were included. Median age was 61 (49–70) and charlson comorbidity index was 2 (1–4). Forty-one (20%) had septic shock and 30-day mortality was observed in 63 (31%). P. Aeruginosawas the causative pathogen in 149 (73%) of patients with Enterobacteriaceae representing the other 54 (27%). Lower respiratory tract infection were the most common (n = 128; 63%). Fifty-five patients received combination therapy (27%) with the most common combination consisting of BL and aminoglycoside (38%). Mortality was observed in 22% of patients receiving combination therapy compared with 35% monotherapy (P = 0.07). Forty-five percent of patients received a PD optimized BL, 25% received a BL not PD optimized, and 30% without a BL. Receipt of PD optimized BL and combination therapy were independent predictors of survival (table).Conclusion PD optimized BL and combination therapy were associated with improved 30-day survival.Table
Survived,
n = 140
Expired,
n = 63
Crude OR (95% CI)
Adjusted OR (95% CI)
Received PD optimized β-lactam71 (78%)20 (22%)2.2 [1.2–4.1]2.2 [1.1–4.3]Septic shock16 (39%)25 (61%)0.2 [0.1–0.4]0.1 [0.1–0.3]Combination therapy44 (80%)11 (20%)1.9 [1–4.6]3.0 [1.3–7.2]Malignancy18 (53%)16 (47%)0.4 [0.2–0.9]0.4 [0.2–0.8]Disclosures
S. L. Davis, Allergan: Grant Investigator and Scientific Advisor, Consulting fee and Research grant. Merck: Grant Investigator and Scientific Advisor, Consulting fee and Research grant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.